Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Obalon Therapeutics Inc.

    NASDAQ: OBLN · Real-Time Price · USD
    3.05
    -0.19 (-5.86%)
    At close: Jun 16, 2021, 6:00 AM

    Obalon Therapeutics Statistics

    Share Statistics

    Obalon Therapeutics has 1.79M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 1.79M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 442.47K

    Failed to Deliver (FTD) Shares

    n/a
    		 n/a

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 441.28K, so 0% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 441.28K

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.95 and the forward PE ratio is null. Obalon Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.95

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 7.34

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 2.5

    P/FCF Ratio

    n/a
    		 -1.1

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Obalon Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.55, with a Debt / Equity ratio of 2.22.

    Current Ratio

    n/a
    		 1.55

    Quick Ratio

    n/a
    		 1.55

    Debt / Equity

    n/a
    		 2.22

    Debt / EBITDA

    n/a
    		 -0.9

    Debt / FCF

    n/a
    		 -0.98

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $794,000

    Profits Per Employee

    n/a
    		 $-6,167,000

    Employee Count

    n/a
    		 2

    Asset Turnover

    n/a
    		 0.15

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1.69M

    Effective Tax Rate

    n/a
    		 13.72%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is -1.24, so Obalon Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -1.24

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 n/a

    200-Day Moving Average

    n/a
    		 n/a

    Relative Strength Index (RSI)

    n/a
    		 n/a

    Average Volume (20 Days)

    n/a
    		 1,508,029

    Income Statement

    In the last 12 months, Obalon Therapeutics had revenue of 1.59M and earned -12.33M in profits. Earnings per share was -1.59.

    Revenue

    n/a
    		 1.59M

    Gross Profit

    n/a
    		 584K

    Operating Income

    n/a
    		 -10.64M

    Net Income

    n/a
    		 -12.33M

    EBITDA

    n/a
    		 -11.49M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -1.59
    Full Income Statement

    Balance Sheet

    The company has 3.9M in cash and 10.36M in debt, giving a net cash position of -6.46M.

    Cash & Cash Equivalents

    n/a
    		 3.9M

    Total Debt

    n/a
    		 10.36M

    Net Cash

    n/a
    		 -6.46M

    Retained Earnings

    n/a
    		 -184.76M

    Total Assets

    n/a
    		 120M

    Working Capital

    n/a
    		 5.11M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -10.41M and capital expenditures -171K, giving a free cash flow of -10.58M.

    Operating Cash Flow

    n/a
    		 -10.41M

    Capital Expenditures

    n/a
    		 -171K

    Free Cash Flow

    n/a
    		 -10.58M

    FCF Per Share

    n/a
    		 -1.36
    Full Cash Flow Statement

    Margins

    Gross margin is 36.78%, with operating and profit margins of -670.15% and -776.7%.

    Gross Margin

    n/a
    		 36.78%

    Operating Margin

    n/a
    		 -670.15%

    Pretax Margin

    n/a
    		 -776.7%

    Profit Margin

    n/a
    		 -776.7%

    EBITDA Margin

    n/a
    		 -723.61%

    EBIT Margin

    n/a
    		 -670.15%

    FCF Margin

    n/a
    		 -666.25%

    Dividends & Yields

    OBLN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for OBLN.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jun 16, 2021. It was a backward split with a ratio of 1:3.

    Last Split Date

    n/a
    		 Jun 16, 2021

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:3

    Scores

    Altman Z-Score

    n/a
    		 -0.09

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist